CG Oncology, Inc.
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.23% | 4.09% | 278.41% | 128.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.23% | 4.09% | 278.41% | 128.00% | -- |
| Cost of Revenue | 72.53% | 42.99% | 50.31% | 57.89% | -- |
| Gross Profit | -73.81% | -43.44% | -48.66% | -57.22% | -- |
| SG&A Expenses | 180.01% | 214.42% | 241.57% | 194.01% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.72% | 105.26% | 119.66% | 126.47% | -- |
| Operating Income | -96.60% | -106.21% | -118.71% | -126.42% | -- |
| Income Before Tax | -100.11% | -91.07% | -87.41% | -87.55% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.11% | -91.07% | -87.41% | -87.55% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.11% | -91.07% | -87.41% | -87.55% | -- |
| EBIT | -96.60% | -106.21% | -118.71% | -126.42% | -- |
| EBITDA | -96.40% | -106.18% | -118.72% | -126.42% | -- |
| EPS Basic | 80.28% | 87.72% | 90.66% | 61.91% | -- |
| Normalized Basic EPS | 74.17% | 83.59% | 87.23% | 58.59% | -- |
| EPS Diluted | 80.28% | 87.72% | 90.66% | 61.91% | -- |
| Normalized Diluted EPS | 74.17% | 83.59% | 87.23% | 58.59% | -- |
| Average Basic Shares Outstanding | 135.03% | 364.80% | 1,385.51% | 1,103.38% | -- |
| Average Diluted Shares Outstanding | 135.03% | 364.80% | 1,385.51% | 1,103.38% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |